Get the Stockscreener App
2.30
8.49%
0.18
Heartbeam Inc stock is traded at $2.30, with a volume of 63.98M.
It is up +8.49% in the last 24 hours and up +37.72% over the past month.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
See More
Previous Close:
$2.12
Open:
$2.505
24h Volume:
63.98M
Relative Volume:
6.75
Market Cap:
$79.22M
Revenue:
-
Net Income/Loss:
$-20.34M
P/E Ratio:
-3.2999
EPS:
-0.697
Net Cash Flow:
$-15.59M
1W Performance:
+215.07%
1M Performance:
+37.72%
6M Performance:
+50.33%
1Y Performance:
-24.59%
1-Day Range:
$2.03
$2.78
1-Week Range:
$0.7251
$2.8199
52-Week Range:
$0.54
$3.48
Heartbeam Inc Stock (BEAT) Company Profile
Name
Heartbeam Inc
Sector
Industry
Phone
408-899-4443
Address
2118 WALSH AVE., SUITE 210, SANTA CLARA
Compare BEAT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAT
Heartbeam Inc
|
2.30 | 73.02M | 0 | -20.34M | -15.59M | -0.697 |
|
VEEV
Veeva Systems Inc
|
223.26 | 37.72B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
70.61 | 13.14B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
96.79 | 8.32B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
43.85 | 8.31B | 550.17M | 201.35M | 232.07M | 1.00 |
|
BTSG
Brightspring Health Services Inc
|
36.54 | 6.47B | 11.99B | 24.18M | 234.31M | 0.2956 |
Heartbeam Inc Stock (BEAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-08-25 | Initiated | H.C. Wainwright | Buy |
| Oct-31-25 | Initiated | Roth Capital | Buy |
| Sep-11-20 | Initiated | Needham | Buy |
| Sep-02-20 | Initiated | Robert W. Baird | Neutral |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Aug-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-26-19 | Reiterated | Dougherty & Company | Buy |
| Jul-26-18 | Reiterated | Lake Street | Buy |
| Apr-26-18 | Reiterated | The Benchmark Company | Buy |
| Feb-23-18 | Reiterated | Dougherty & Company | Buy |
| Nov-08-17 | Reiterated | Dougherty & Company | Buy |
| Oct-26-17 | Initiated | Raymond James | Outperform |
| Oct-24-17 | Initiated | SunTrust | Buy |
| Aug-09-17 | Reiterated | Dougherty & Company | Buy |
| Jul-19-17 | Reiterated | The Benchmark Company | Buy |
| Apr-11-17 | Reiterated | Dougherty & Company | Buy |
| Dec-02-16 | Initiated | Dougherty & Company | Buy |
| Sep-13-16 | Initiated | Sidoti | Buy |
| Aug-03-16 | Reiterated | The Benchmark Company | Buy |
| Jul-28-15 | Reiterated | Dougherty & Company | Buy |
| Oct-24-13 | Initiated | The Benchmark Company | Buy |
| Aug-21-13 | Initiated | Dougherty & Company | Buy |
View All
Heartbeam Inc Stock (BEAT) Latest News
HeartBeam Shares Skyrocket: FDA Boost - timothysykes.com
HeartBeam Soars with FDA Approval for Breakthrough ECG Technology - timothysykes.com
HeartBeam Stock Soars: Should You Buy? - timothysykes.com
Heartbeam stock is a buy, this analyst says - Cantech Letter
Benchmark Upgrades HeartBeam (BEAT) - Nasdaq
HeartBeam Stock Surges: Analyzing the Uptrend - StocksToTrade
Why Is Micro Cap HeartBeam Stock Surging On Wednesday? - Sahm
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
HeartBeam swells on turning FDA rejection into ECG clearance - Fierce Biotech
3 Penny Stocks to Watch Now, 12/11/25 - TipRanks
HeartBeam receives US FDA clearance for at-home arrhythmia assessment with cable-free 12-lead ECG - Cardiac Rhythm News
HeartBeam (BEAT) Receives Upgrade from Benchmark Analyst | BEAT Stock News - GuruFocus
HeartBeam go-to-market strategy remains on track, says Benchmark - TipRanks
HeartBeam stock soars as H.C. Wainwright doubles price target on FDA clearance - Investing.com India
HeartBeam sinks after ‘Not Substantially Equivalent’ letter from FDA - MSN
BEAT Secures FDA Nod for First Cable-Free At-Home 12-Lead ECG System - Nasdaq
HeartBeam Receives FDA Clearance for 12-Lead ECG Synthesis Software Following Appeal - citybuzz
HeartBeam announces FDA clearance for 12-lead ECG synthesis software - MSN
Oracle, Synopsys, Heartbeam, Planet Labs And Adobe: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Heartbeam Inc. (BEAT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
HC Wainwright & Co. Maintains HeartBeam (BEAT) Buy Recommendation - Nasdaq
Heartbeam wins appeal, gains FDA clearance - BioWorld MedTech
FDA Greenlight Sends HeartBeam, Photronics, And Designer Brands Shares Climbing - Finimize
HeartBeam (BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal - Yahoo Finance
HeartBeam’s Leap: Should Investors Be Wary? - StocksToTrade
FDA Clears HeartBeam Cable-free 12-lead ECG - respiratory-therapy.com
HeartBeam Secures FDA Clearance for 12-Lead ECG Synthesis Software Following Appeal - citybuzz
HeartBeam (BEAT) Stock: Surges 50% After FDA Grants Clearance For its 12-lead ECG Device - parameter.io
HeartBeam (BEAT) Analyst Rating: HC Wainwright Raises Price Targ - GuruFocus
HeartBeam price target raised to $5.50 from $2.50 at H.C. Wainwright - TipRanks
FDA clears HeartBeam’s at-home arrhythmia assessment tool - Yahoo
Weekly Trades: Is HeartBeam Inc stock recession proofTrade Entry Report & Community Trade Idea Sharing Platform - BỘ NỘI VỤ
HeartBeam Receives FDA Clearance for 12-Lead ECG for At-Home Arrhythmia Assessment - marketscreener.com
HeartBeam (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal - TradingView
HeartBeam Wins FDA Nod for Cable-Free 12-Lead ECG for Home Arrhythmia Assessment - Medical Product Outsourcing
HeartBeam shares skyrocket after FDA signs off on 12-lead ECG synthesis software - MSN
HeartBeam Shares Surge: Buy Signal? - timothysykes.com
HeartBeam : Earnings Documents - marketscreener.com
HeartBeam stock soars after FDA clearance for 12-lead ECG synthesis software - Investing.com Nigeria
Why Is HeartBeam Stock (BEAT) Up Today? - TipRanks
Heartbeam rises after FDA clears its cable‑free ECG software - TradingView
HeartBeam’s 12-lead ECG synthesis software receives FDA clearance By Investing.com - Investing.com Australia
HeartBeam’s 12-lead ECG synthesis software receives FDA clearance - Investing.com India
HeartBeam earns FDA clearance for first-ever cable-free 12-lead ECG for at-home arrhythmia assessment - MassDevice
Why Did BEAT Stock Rocket 72% In Pre-Market Today? - Stocktwits
Heartbeam, Inc.Common Stock (Nasdaq:BEAT) Stock Quote - Markets Financial Content
HC Wainwright & Co. Initiates Coverage of HeartBeam (BEAT) with Buy Recommendation - Nasdaq
An analyst sees good growth prospects for HeartBeam Inc (BEAT) - Setenews
HeartBeam (BEAT) Receives 'Buy' Rating from HC Wainwright & Co. - GuruFocus
HC Wainwright Initiates HeartBeam at Buy With $2.50 Price Target - marketscreener.com
HeartBeam initiated with a Buy at H.C. Wainwright - TipRanks
Heartbeam Inc Stock (BEAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
6.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):